Skip to main content
Year archive

Zelluna ASA — 2023 filings

All 61 regulatory filings released by Zelluna ASA (ULTI) in 2023, sourced directly from the official regulator.

61 Filings
2023 Period
2023 filings (61)
Filing Released Lang
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-12-19 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-12-19 English
Financial calendar
Report Publication Announcement
2023-12-18 English
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
Regulatory Filings
2023-12-18 English
Ultimovacs Announces Resignation of Aitana Peire from Board of Directors
Board/Management Information
2023-11-28 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-11-21 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-11-21 English
Ultimovacs ASA: New share capital registered
Share Issue/Capital Change
2023-11-13 English
Ultimovacs ASA: Share capital increase related to exercise of options
Share Issue/Capital Change
2023-11-09 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-11-08 Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-11-08 English
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
Investor Presentation
2023-11-08 English
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
Interim / Quarterly Report Q3 2023
2023-11-08 English
Ultimovacs ASA Reports Third Quarter 2023 Financial Results and Provides General Business Update
Earnings Release Q3 2023
2023-11-08 English
Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation
Report Publication Announcement
2023-11-02 English
Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma
Regulatory Filings
2023-11-02 English
Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024
Regulatory Filings
2023-10-31 English
Ultimovacs Announces Webcast to Elaborate on the Results from Randomized UV1 Phase II NIPU Trial in Malignant Mesothelioma
Regulatory Filings
2023-10-25 English
Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine
Earnings Release Q4 2023
2023-10-12 English
Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma
Regulatory Filings
2023-10-09 English
Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023
Regulatory Filings
2023-09-27 English
Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update
Investor Presentation
2023-08-22 English
Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update
Interim / Quarterly Report Q2 2023
2023-08-22 English
Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update
Report Publication Announcement Q2 2023
2023-08-22 English
Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation
Report Publication Announcement
2023-08-16 English
Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients
Regulatory Filings
2023-08-03 English
Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results
Investor Presentation
2023-06-28 English
Ultimovacs' Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award's Honorary Prize as an Outstanding Pioneer Against Cancer
Board/Management Information
2023-06-22 English
Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine
Earnings Release Q2 2023
2023-06-19 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-06-08 Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-06-08 English
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-06-08 Norwegian
Ultimovacs ASA: Mandatory notification of trade by primary insider
Director's Dealing
2023-06-08 English
Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma
Regulatory Filings
2023-06-07 English
Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update
Interim / Quarterly Report Q1 2023
2023-05-10 English
Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update
Investor Presentation Q1 2023
2023-05-10 English
Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update
Earnings Release Q1 2023
2023-05-10 English
Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation
Report Publication Announcement
2023-05-03 English
Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma
Regulatory Filings
2023-04-25 English
Ultimovacs ASA - Share Option Program
Remuneration Information
2023-04-21 English
Ultimovacs ASA - Annual General Meeting held on 20 April 2023
AGM Information
2023-04-20 Norwegian
Ultimovacs ASA - Annual General Meeting held on 20 April 2023
AGM Information
2023-04-20 English
Ultimovacs ASA - Disclosure of voting rights of Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements
2023-04-14 English
Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations
Regulatory Filings
2023-04-13 English
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
AGM Information
2023-03-24 Norwegian
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
AGM Information
2023-03-24 English
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
Remuneration Information
2023-03-24 English
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
Remuneration Information
2023-03-24 English
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
Annual Report FY 2022
2023-03-24 English
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
AGM Information
2023-03-24 English
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
AGM Information
2023-03-24 Norwegian
Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023
AGM Information
2023-03-24 English
Ultimovacs ASA: Annual Report 2022
Annual Report (ESEF) FY 2022
2023-03-24 English
Ultimovacs ASA: Annual Report 2022
Annual Report FY 2022
2023-03-24 English
Ultimovacs ASA: Annual Report 2022
Report Publication Announcement
2023-03-24 English
Ultimovacs to Present at Cowen Healthcare Conference
Regulatory Filings
2023-02-27 English
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
Investor Presentation
2023-02-16 English
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
Interim / Quarterly Report Q4 2022
2023-02-16 English
Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update
Earnings Release Q4 2022
2023-02-16 English
Ultimovacs ASA: Invitation to fourth quarter 2022 results webcast presentation
Report Publication Announcement
2023-02-09 English
Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma
Regulatory Filings
2023-01-23 English